Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | STS | P08842 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6981012 | 1.00 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL6180319 | 0.94 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL30706072 | 0.94 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL29132053 | 0.93 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL29132279 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL27308756 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL8309709 | 0.92 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL26924802 | 0.91 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL25192128 | 0.90 | STS (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL25265622 | 0.90 | STS (0.52) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070929-A1 | METHODS AND COMPOSITIONS FOR MODULATING KRAS(G12D) | RANOK THERAPEUTICS HANGZHOU CO LTD (CN) | 2026-03-12 | — | — | US | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| CN-120018863-A | Methods and compositions for modulating KRAS (G12D) | 珃诺生物医药科技(杭州)有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4506344-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | Bebetter Med Inc. (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | BEBETTER MED INC. (CN) | 2025-01-30 | — | — | US | disclosed |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2024-08-29 | — | — | US | disclosed |
| CN-118119609-A | Imidazole derivatives and their use as antibiotics | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4370514-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2024-05-22 | — | — | EP | disclosed |
| CN-116615417-B | 1, 4-Diheterocyclic group substituted aromatic ring or aromatic heterocyclic compound and application thereof | 广州必贝特医药股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023285497-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022198112-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER REC TECH LTD (GB) | 2014-11-27 | — | — | US | disclosed |
| US-8778925-B2 | Pyridine and pyrimidine based compounds as Wnt signaling pathway inhibitors for the treatment of cancer | CANCER RESEARCH TECHNOLOGY LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| CN-102171202-A | Pyridine and pyrimidine based compounds as WNT signaling pathway inhibitors for the treatment of cancer | CANCER REC TECH LTD | 2011-08-31 | — | — | CN | disclosed |
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED | 2011-08-04 | — | — | US | disclosed |
| EP-2331523-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | Cancer Research Technology Limited (GB) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010041054-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190297-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | SMN1; SMN2 4623/4885NPC1 2612/4885RAB9A 2116/4885 |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885 |
| US-20260070929-A1 | METHODS AND COMPOSITIONS FOR MODULATING KRAS(G12D) | KRAS, HRAS, NRAS | SMN1; SMN2 3326/4885NPC1 1581/4885RAB9A 355/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885 |
| US-20140350015-A1 | PYRIDINE AND PYRIMIDINE BASED COMPOUNDS AS WNT SIGNALING PATHWAY INHIBITORS FOR THE TREATMENT OF CANCER | WNT1, CTNNB1, WNT3 | SMN1; SMN2 4623/4885NPC1 2612/4885RAB9A 2116/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | SMN1; SMN2 3629/4885NPC1 1190/4885RAB9A 547/4885 |
| US-20250034116-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | CYP46A1, CYP4A22, CYP2C19 | SMN1; SMN2 4448/4885NPC1 503/4885RAB9A 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.